The stock of Amgen, Inc. (NASDAQ:AMGN) is a huge mover today! About 922,121 shares traded hands. Amgen, Inc. (NASDAQ:AMGN) has risen 16.62% since March 9, 2016 and is uptrending. It has outperformed by 9.21% the S&P500.
The move comes after 9 months positive chart setup for the $120.06 billion company. It was reported on Oct, 12 by Barchart.com. We have $267.86 PT which if reached, will make NASDAQ:AMGN worth $75.64B more.
Analysts await Amgen, Inc. (NASDAQ:AMGN) to report earnings on October, 26. They expect $2.79 earnings per share, up 2.57% or $0.07 from last year’s $2.72 per share. AMGN’s profit will be $2.04 billion for 14.72 P/E if the $2.79 EPS becomes a reality. After $2.84 actual earnings per share reported by Amgen, Inc. for the previous quarter, Wall Street now forecasts -1.76% negative EPS growth.
Amgen, Inc. (NASDAQ:AMGN) Ratings Coverage
Out of 16 analysts covering Amgen Inc. (NASDAQ:AMGN), 9 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 56% are positive. Amgen Inc. has been the topic of 28 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Citigroup maintained it with “Neutral” rating and $172 target price in Wednesday, September 28 report. The firm has “Buy” rating by Argus Research given on Monday, February 8. Atlantic Securities initiated Amgen, Inc. (NASDAQ:AMGN) rating on Friday, December 18. Atlantic Securities has “Overweight” rating and $202 price target. Piper Jaffray maintained the stock with “Overweight” rating in Saturday, August 29 report. As per Tuesday, December 15, the company rating was upgraded by Morgan Stanley. The firm earned “Buy” rating on Monday, September 7 by UBS. The firm earned “Market Perform” rating on Friday, February 5 by Leerink Swann. The firm has “Outperform” rating given on Wednesday, January 20 by Credit Suisse. As per Friday, August 26, the company rating was initiated by Gabelli. As per Tuesday, September 1, the company rating was initiated by Raymond James.
According to Zacks Investment Research, “Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.”
Insitutional Activity: The institutional sentiment increased to 1.28 in 2016 Q2. Its up 0.21, from 1.07 in 2016Q1. The ratio increased, as 56 funds sold all Amgen, Inc. shares owned while 422 reduced positions. 77 funds bought stakes while 533 increased positions. They now own 577.82 million shares or 7.76% less from 626.39 million shares in 2016Q1.
Baring Asset holds 0.62% or 49,992 shares in its portfolio. Freestone Capital Limited Liability has 0.1% invested in the company for 6,572 shares. Moreover, Sivik Glob Healthcare Limited Company has 2.65% invested in Amgen, Inc. (NASDAQ:AMGN) for 35,000 shares. Toth Advisory Corp has 7,244 shares for 0.34% of their US portfolio. Haverford Trust accumulated 38,418 shares or 0.15% of the stock. Doheny Asset Ca has 0.82% invested in the company for 10,783 shares. Aston Asset Mngmt Ltd Com owns 9,727 shares or 0.9% of their US portfolio. Kcm Advsrs Ltd Limited Liability Company accumulated 16,031 shares or 0.17% of the stock. Palladium Prtn Limited Liability Corp accumulated 1.4% or 100,956 shares. Cibc Ww Mkts has 37,080 shares for 0.02% of their US portfolio. Opus Invest Inc has 33,600 shares for 0.9% of their US portfolio. Sarasin & Prns Ltd Liability Partnership, a United Kingdom-based fund reported 1.32M shares. Endurance Wealth Mgmt accumulated 0.04% or 1,247 shares. Mathes Company Incorporated last reported 13,620 shares in the company. The New York-based Burnham Asset Mngmt Corp Ny has invested 0.86% in Amgen, Inc. (NASDAQ:AMGN).
Insider Transactions: Since April 29, 2016, the stock had 0 insider purchases, and 4 insider sales for $9.12 million net activity. Shares for $4.62M were sold by Balachandran Madhavan. 3,312 shares were sold by BALTIMORE DAVID, worth $520,684. Harper Sean E sold $3.46M worth of Amgen, Inc. (NASDAQ:AMGN) on Friday, April 29. Such Annette Louise also sold $523,758 worth of Amgen, Inc. (NASDAQ:AMGN) shares.
Another recent and important Amgen, Inc. (NASDAQ:AMGN) news was published by 247Wallst.com which published an article titled: “Short Sellers Have Mixed Views on Major Biotechs” on October 12, 2016.
AMGN Company Profile
Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Firm discovers, develops, makes and delivers various human therapeutics. The Company’s business segment is human therapeutics. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Firm focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.